Aptose Biosciences Inc (APTO)

[Tartiaboy]

This quizartinib NDA targets first line "fit" FLT3-ITD positive AML patients. The potential first line Tuspetinib (combination) target population is much larger than this. It may ultimately include both fit and unfit AML patients with and without AML-flt3 mutations. AND it has a much better safety profile. The market will not recognize this until APTO posts clinical results with various combination such as Tusp+Ven and Tusp+Ven+hypometh agents. It will take another year to get enough data for the market to begin to see this potential.

My dream scenario would be if they can combine TUSP and LUX into combinations. I don't look at these as two Flt-3 inhibitors; I see them as two multi-kinase inhibitors with complementary profiles.

You and I disagree on a key point. You seem to see the need for an approval before APTO gets any street credibility for Tuspetinib. I think they need to see the potential of Tuspetinib in combinations.

You may recall that Argule got a $2B buyout on surprise RT data long before any potential approvals were envisioned. I think APTO will eventually see multi-billion valuation-perhaps within the next 2-3 years.